Intech Biopharm Ltd

Intech Biopharm Ltd has a market price of 15.75 TWD, resulting in a market capitalization of 2,809,878,750 TWD. The company's price-to-book ratio is 2.57, and its price-to-tangible-book ratio is also 2.57, indicating that the market is valuing the company's equity at a premium relative to its book value. The enterprise value to EBITDA ratio is -59.97, and the enterprise value to revenue ratio is 289.54, suggesting that the company is not currently generating positive earnings and is valued at a high multiple of its revenue.

The company's profitability metrics are concerning, with a return on equity of -6.84% and a return on assets of -2.75%, both significantly below the industry median. The gross profit is negative at -33,104,000 TWD, and the operating income is also negative at -71,298,000 TWD, indicating that the company is not generating sufficient revenue to cover its operating costs. The net income is -74,901,000 TWD, reflecting a substantial loss for the period.

Intech Biopharm Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements. The company does not provide detailed geographic revenue breakdowns, but its operations are primarily based in Taiwan. The lack of geographic diversification increases the company's exposure to local economic and regulatory risks.

The company's growth trajectory is negative, with a significant decline in revenue and profitability. The operating cash flow is -46,926,000 TWD, and the free cash flow is -71,269,000 TWD, indicating that the company is not generating positive cash flow from its operations. The capital expenditure is -17,716,000 TWD, suggesting that the company is not investing in new projects or expanding its operations.

The company faces several risk factors, including liquidity risk due to its negative net cash position after subtracting total debt. The debt-to-equity ratio is 1.38, indicating a high level of leverage. The current ratio is 0.95, suggesting that the company may struggle to meet its short-term obligations. The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.

Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company has not issued any new shares or raised additional capital recently. The lack of recent positive developments may affect investor confidence and the company's ability to attract new funding.

Revenue surged 170.3% year-over-year to TWD 107.5 million, demonstrating significant top-line growth momentum.

The four-year revenue CAGR of 28.9% indicates a strong historical trajectory of expanding sales volume.

Long-term debt declined to TWD 1.19 billion, indicating a modest reduction in leverage compared to prior periods.

The company faces high credit risk, signaling significant concerns regarding its ability to meet financial obligations.

Net margin of -5.07% ranks in the bottom quartile among 826 pharmaceutical peers, highlighting poor profitability.

Debt-to-equity ratio of 1.38 places the firm in the bottom quartile, indicating excessive leverage relative to peers.